Could prolactin receptor gene polymorphism play a role in pathogenesis of breast carcinoma?

References

• Feuer EJ, Wun LM, Boring CC, Flanders WD, Timmel MJ, Tong T. The lifetime risk of developing breast cancer. J Natl Cancer Inst 1993;85:892–7
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Wood WC, Senn HJ, Glick JH, Gelber RD. IX. International consensus conference on primary treatment of breast cancer. Recent Results Cancer Res 1996;140:325–3
   PubMedGoogle Scholar
• Bennett IC, Gattas M, Teh BT. The genetic basis of breast cancer and its clinical implications. Aust New Zealand J Surg 1999;69:95–105
   PubMedGoogle Scholar
• Tripathy D, Benz C. Growth factors and their receptors. Hematol Oncol Clin North Am 1994 ;8:29–50
   PubMed Web of Science ®Google Scholar
• Bazan JF. Haemopoietic receptors and helical cytokines. Immunol Today 1990;11:350–4
   PubMedGoogle Scholar
• Llovera M, Touraine P, Kelly PA, Goffin V. Involvement of prolactin in breast cancer: redefining the molecular targets. Exp Gerontol 2000;35:41–51
   PubMed Web of Science ®Google Scholar
• Ali S, Pellegrini I, Kelly PA. A prolactin-dependent immune cell line (Nb2) expresses a mutant form of prolactin receptor. J Biol Chem 1991;266: 20110–7
   Google Scholar
• Sissom JF, Eigenbrodt ML, Porter JC. Anti-growth action on mouse mammary and prostate glands of a monoclonal antibody to prolactin receptor. Am J Pathol 1988;133:589–95
   Google Scholar
• Wennbo H, Gebre-Medhin M, Gritli-Linde A, Ohlsson C, Isaksson OG, Tornell J. Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumours in transgenic mice. J Clin Invest 1997;100:2744–51
   PubMed Web of Science ®Google Scholar
• Canbay E, Norman M, Kilic E, Goffin V, Zachary I. Prolactin stimulates the JAK2 and focal adhesion kinase pathways in human breast carcinoma T47-D cells. Biochem J 1997;324 (Pt 1):231–6
   Google Scholar
• Bonneterre J, Peyrat JP, Beuscart R, Demaille A. Biological and clinical aspects of prolactin receptors (PRL-R) in human breast cancer. J Steroid Biochem Mol Biol 1990;37:977–81
   PubMed Web of Science ®Google Scholar
• Hankinson SE, Willett WC, Michaud DS, et al. Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1999;91:629–34
   PubMed Web of Science ®Google Scholar
• Goffin V, Touraine P, Pichard C, Bernichtein S, Kelly PA. Should prolactin be reconsidered as a therapeutic target in human breast cancer. Mol Cell Endocrinol 1999;151:79–87
   Google Scholar
• Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev 1998;19:225–68
   Google Scholar
• Touraine P, Martini JF, Zafrani B, et al. Increased expression of prolactin receptor gene assessed by quantitative polymerase chain reaction in human breast tumours versus normal breast tissues. J Clin Endocrinol Metab 1998;83:667–74
   PubMed Web of Science ®Google Scholar
• Mertani HC, Garcia-Caballero T, Lambert A, et al. Cellular expression of growth hormone and prolactin receptors in human breast disorders. Int J Cancer 1998;79:202–11
   PubMed Web of Science ®Google Scholar
• Lee RC, Walters JA, Reyland ME, Anderson SM. Constitutive activation of the prolactin receptor results in the induction of growth factor-independent proliferation and constitutive activation of signaling molecules. J Biol Chem 1999;274:10024–34
   PubMed Web of Science ®Google Scholar
• Gonda TJ, D’Andrea RJ. Activating mutations in cytokine receptors: implications for receptor function and role in disease. Blood 1997;89:355–69
   PubMed Web of Science ®Google Scholar
• Glasow A, Horn LC, Taymans SE, et al. Mutational analysis of the PRL receptor gene in human breast tumours with differential PRL receptor protein expression. J Clin Endocrinol Metab 2001;86:3826–32
   PubMed Web of Science ®Google Scholar
• Feig BW, Berger DH, Fuhrman GM. The M.D. Anderson surgical oncology handbook. Philadelphia: Lippincott Williams & Wilkins;1999
   Google Scholar
• Hu ZZ, Zhuang L, Meng J, Leondires M, Dufau ML. The human prolactin receptor gene structure and alternative promoter utilization: the generic promoter hPIII and a novel human promoter hP(N). J Clin Endocrinol Metab 1999;84:1153–6
   Google Scholar
• Ormandy CJ, Binart N, Helloco C, Kelly PA. Mouse prolactin receptor gene: genomic organization reveals alternative promoter usage and generation of isoforms via alternative 3′-exon splicing. DNA Cell Biol 1998;17:761–70
   PubMed Web of Science ®Google Scholar
• Kline JB, Roehrs H, Clevenger CV. Functional characterization of the intermediate isoform of the human prolactin receptor. J Biol Chem 1999;274:35461–8
   Google Scholar
• Mansfield CM. A review of the etiology of breast cancer. J Natl Med Assoc 1993 ;85:217–21
   PubMed Web of Science ®Google Scholar
• Shiu RP, Murphy LC, Tsuyuki D, Myal Y, Lee-Wing M, Iwasiow B. Biological actions of prolactin in human breast cancer. Recent Prog Horm Res 1987;43:277–303
   PubMedGoogle Scholar
• Clevenger CV, Medaglia MV. The protein tyrosine kinase P59fyn is associated with prolactin (PRL) receptor and is activated by PRL stimulation of T-lymphocytes. Mol Endocrinol 1994;8:674–81
   PubMed Web of Science ®Google Scholar
• Erwin RA, Kirken RA, Malabarba MG, Farrar WL, Rui H. Prolactin activates Ras via signaling proteins SHC, growth factor receptor bound 2, and son of sevenless. Endocrinology 1995;136: 3512–8
   Google Scholar
• Al-Sakkaf KA, Dobson PR, Brown BL. Activation of phosphatidylinositol 3-kinase by prolactin in Nb2 cells. Biochem Biophys Res Commun 1996;221: 779–84
   Google Scholar
• Savage MO, Woods KA, Johnston LB, Postel-Vinay MC, Amselem S, Clark AJ. Defects of the growth hormone receptor and their clinical implications. Growth Horm IGF Res 1999;9(Suppl A):57–61
   Google Scholar
• Baumgartner JW, Wells CA, Chen CM, Waters MJ. The role of the WS_WS motif in growth hormone receptor function. J Biol Chem 269;299094–101
   Google Scholar